Pattern is developing PPI-100, an immune-reprogramming therapeutic that mobilizes innate immunity to overcome the key immune failures that drive both cancers and infectious diseases. Capitalizing on extensive nonclinical and clinical data, PPI-100 is being developed for different oncology indications. Pattern's initial focus is on the perioperative setting — a large market opportunity to address the ~40% relapse rate in cancer patients within five years of surgery — and the company intends filing a regulatory submission to commence a clinical study in this indication in 2026.

PPI-100 builds on the proven safety and efficacy of a predecessor product, which received regulatory approval and widespread clinical use in various ex-US markets for infectious diseases. Additionally, this past year a dose-escalation treatment & testing program focused on late-stage cancer patients has been conducted with the earlier product at a German cancer center, which has generated very useful de-risking safety, PD and efficacy data.

The new product, PPI-100, offers significant improvements and has robust intellectual property protection. Pattern collaborates with leading institutions including Harvard’s Massachusetts General Hospital, MD Anderson, University of Toronto, and McGill University.

Pattern ImmunoTx

Org chart

Teams

Offices

Pattern ImmunoTx

Org chart

Teams

Offices

Related companies